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Taylor and colleagues [1] examined the time course of 
gene expression proﬁ  le changes in estrogen (E2)-treated 
and E2 and tamoxifen-treated mouse xenografts. Th  e 
authors pre  sented three distinct categories of gene 
expression temporal proﬁ  les, each characterized by two 
sets of genes. Diﬀ  erentially expressed genes at some early 
time points following treatment were found to be 
prognostic of survival in clinical data sets, but not those 
identiﬁ   ed at other time points. Th  is implies that the 
timing of the post-treatment sample for gene expression 
analysis will be critical for the development of prognostic 
and predictive biomarkers.
Adjuvant endocrine treatment in estrogen receptor-
positive (ER+) breast cancer patients reduces the risk of 
relapse and death from breast cancer [2], but large 
numbers of patients still die of endocrine therapy-
resistant disease [3]. Researchers have therefore devoted 
intensive eﬀ   orts to identify molecular biomarkers to 
predict response to endocrine treatment and, in spite of 
the inherent heterogeneity among ER+ breast tumors, 
gene expression signatures have been successfully 
developed [4-6]. However, the existing signatures are 
based on gene expression information in a single baseline 
tumor sample that may not capture all the biological 
information necessary for predictive accuracy. Clinically, 
patients fall into three broad categories, continuously 
responding, continuously resistant, and a substantial 
group of patients with an initial response followed by a 
transition at varying rates to an acquired resistance 
phenotype. Late recurrence in resistant patients might be 
avoided if these tumors could be identiﬁ  ed early, before 
the onset of clinical resistance, and subjected to an 
eﬀ  ective salvage intervention. Th   erefore, the discovery of 
gene signatures diﬀ  erentiating the three response groups 
logically requires the identiﬁ  cation of temporal changes 
in gene expression along the treatment course. Th  e  paper 
by Taylor and colleagues [1] illustrates this principle.
Microarray gene expression data were used by Taylor 
and colleagues [1] for discovery and validation of gene 
expression signatures. Overall, the paper is a good 
example of the practice of microarray data analysis. Raw 
data were deposited in CaArray [7] to be available to the 
public, which encourages research reproducibility. After 
the gene discovery process, validation in multiple inde-
pendent public datasets was carried out. An important 
caveat of this aspect of the paper is that these datasets are 
not particularly suitable to assess the primary hypothesis 
because all these studies report only baseline array gene 
expression levels - not treatment-induced changes. Th  e 
true test of the approach would be to compare the 
prognostic information in the baseline sample with post-
treatment samples taken at diﬀ  erent time points from the 
same patient. Moreover, signiﬁ  cance of potential therapy-
response gene signatures in treated versus untreated 
patient cohorts should be interpreted with caution.
Th  e paper also identiﬁ   es areas for methodological 
improvement. Th  e data analysis is limited to two-class 
comparison at each individual time point, which neglects 
time dependency in gene expression proﬁ  ling. Th  e  deﬁ  -
nition of the six sets of genes is subjectively deter  mined 
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Microarray data have been widely utilized to discover 
biomarkers predictive of response to endocrine 
therapy in estrogen receptor-positive breast cancer. 
Typically, these data have focused on analyses 
conducted on the diagnostic specimen. However, 
dynamic temporal changes in gene expression 
associated with treatment may deliver signifi  cant 
improvements to the current generation of predictive 
models. We present and discuss some statistical issues 
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conducted studies to model the prognostic potential 
of gene expression changes that occur after endocrine 
treatment.
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gene expression proﬁ  ling would be better analyzed as a 
whole by functional data analysis techniques [8,9]. Rather 
than traditional cluster analysis [10], cluster tools 
designed speciﬁ   cally for time course gene expression 
data, such as CAGED (Cluster Analysis of Gene 
Expression Dynamics) [11], would probably serve better. 
Furthermore, the class comparison in the paper depends 
on fold change alone, a common error in the analysis of 
microarray data [12]. Fold change is easy to calculate and 
understand; however, it is a single ratio without 
consideration of variability. Use of fold change usually 
leads to high false positives since small changes in genes 
with low expression levels can lead to large fold change. 
Th   e hierarchical algorithm is applied to public microarray 
data in the paper to divide samples into low and high 
expression groups. Th   e use of unsupervised clustering for 
class prediction is very subjective [12]. Th  e two-color 
microarray design was used while the authors 
commented on the possible beneﬁ  ts of using a one-color 
design. Th   e two-color with common reference design has 
been the most widely used in microarray experiments for 
its ease of implementation and analysis. Th  e one-color 
design has recently emerged to be a favorite because of 
its simplicity and ﬂ   exibility after conﬁ  rmation  of 
comparative data quality to its two-color counterpart. 
However, the two-color design is still reported to exhibit 
a small advantage in detecting diﬀ  erential  genes, 
especially for genes of small fold changes [13].
In their paper, Taylor and colleagues speculated that 
the ‘early/transient’ expression changes are the causative 
events for tumor inhibition. Th   is might be true but needs 
to be investigated more carefully in future studies. 
Meanwhile, it is important to acknowledge the fact that 
some patients who respond initially and exhibit the early/
transient expression change may acquire resistance 
gradually. It will be challenging to pick these patients out 
for individualized treatment planning as the critical 
changes may take place only after months or years of 
endocrine therapy exposure.
In conclusion, we fully agree on the importance of 
investigating temporal gene expression proﬁ  ling  for 
prediction of treatment response. More well-planned 
studies will be required for insights into these 
complicated data sets and variability in response to 
treatment will be an important consideration. Th   e task of 
obtaining consecutive gene expression proﬁ  ling  at 
multiple time points remains a challenging prospect but 
might be feasible in well planned neoadjuvant endocrine 
therapy studies where patients might be triaged to 
alternative therapy if an unresponsive gene expression 
proﬁ  le emerged, even when the patient was in response 
clinically.
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